Saturday, April 16, 2016 4:28:11 PM
ENDV.....Bioelectronics
While bioelectronic medicine, which seeks to use electrical pulses to trick the body into healing itself, may seem like a big idea in some futuristic sci-fi story, the reality is it's already here and happening now.
Bioelectronic medicine is a new field but the hope and promise of this approach is significant. Can you imagine a world without Crohn's disease, Alzheimer's, or heart failure? These are inflammatory diseases that affect millions of people each and every day. But, what if they didn't have to suffer or live the rest of their lives on drugs? Bioelectronic medicine, which is seeking to address these diseases, is not an innovation but rather a revolution. A revolution seen replacing billions of dollars in drugs replaced with safer and potentially more effective devices.
Bioelectronic medicine at its core seeks to control the inflammatory response which is critical to healing but can be very dangerous and damaging if too much of it persists.
This new field of medicine has attracted the attention and investment of big pharma, such as GlaxoSmithKline (GSK) and The Feinstein Institute for Medical Research, which has created a tiny pill-sized implantable device that can literally reroute the neuro-pathways of sick patients by tapping into the vagus nerve, located on the side of the neck. This device works like a pacemaker, in that it hits the off-switch on the vagus nerve, causing it to turn off its inflammatory response. This device is now being engineered and developed by California's SetPoint Medical.
One bioelectronics player we see having the potential to grow faster than the market is Endonovo Therapeutics, Inc. (OTCQB:ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine.
Endonovo's bioelectronic device uses a different approach than others in the field; it is a non-implantable device that uses a pulsed electromagnetic field to deliver electrical stimulation, rather than implantable electrodes.
ENDV's devices are based on the Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA.
ENDV's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for preventing and treating vital organ failure through the reduction of inflammation and cell death, and the promotion of regeneration. It has been identified in pre-clinical studies to be an innovative approach for treating acute inflammation.
The company is targeting inflammatory conditions in vital organs and has set its initial concentration on treating inflammation in the liver. If Endonovo can treat inflammation in vital organs then its technology would truly be a game changer as inflammation is regarded as the root of all disease.
ENDV is also using bioelectronics to create more potent cell therapies and next-generation biologics by simulating adult stem cells using its Cytotronics™ platform.
ENDV just received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." When the USPTO intends to issue a patent, it sends the applicant a Notice of Allowance, which is what ENDV just received. The final steps required before the actual patent is issued are essentially a formality (applicant pays required issue fee and submits any final drawings). So essentially this news means ENDV has received patent approval.
The patent application covers the production of fully human biological molecules, including growth factors and cytokines in adult stem cells using the Company's proprietary technologies. This technology has applications from the production of biological molecules, such as cytokines for research purposes to the creation of next-generation biologics.
Daily
ENDV
While bioelectronic medicine, which seeks to use electrical pulses to trick the body into healing itself, may seem like a big idea in some futuristic sci-fi story, the reality is it's already here and happening now.
Bioelectronic medicine is a new field but the hope and promise of this approach is significant. Can you imagine a world without Crohn's disease, Alzheimer's, or heart failure? These are inflammatory diseases that affect millions of people each and every day. But, what if they didn't have to suffer or live the rest of their lives on drugs? Bioelectronic medicine, which is seeking to address these diseases, is not an innovation but rather a revolution. A revolution seen replacing billions of dollars in drugs replaced with safer and potentially more effective devices.
Bioelectronic medicine at its core seeks to control the inflammatory response which is critical to healing but can be very dangerous and damaging if too much of it persists.
This new field of medicine has attracted the attention and investment of big pharma, such as GlaxoSmithKline (GSK) and The Feinstein Institute for Medical Research, which has created a tiny pill-sized implantable device that can literally reroute the neuro-pathways of sick patients by tapping into the vagus nerve, located on the side of the neck. This device works like a pacemaker, in that it hits the off-switch on the vagus nerve, causing it to turn off its inflammatory response. This device is now being engineered and developed by California's SetPoint Medical.
One bioelectronics player we see having the potential to grow faster than the market is Endonovo Therapeutics, Inc. (OTCQB:ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine.
Endonovo's bioelectronic device uses a different approach than others in the field; it is a non-implantable device that uses a pulsed electromagnetic field to deliver electrical stimulation, rather than implantable electrodes.
ENDV's devices are based on the Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA.
ENDV's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for preventing and treating vital organ failure through the reduction of inflammation and cell death, and the promotion of regeneration. It has been identified in pre-clinical studies to be an innovative approach for treating acute inflammation.
The company is targeting inflammatory conditions in vital organs and has set its initial concentration on treating inflammation in the liver. If Endonovo can treat inflammation in vital organs then its technology would truly be a game changer as inflammation is regarded as the root of all disease.
ENDV is also using bioelectronics to create more potent cell therapies and next-generation biologics by simulating adult stem cells using its Cytotronics™ platform.
ENDV just received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." When the USPTO intends to issue a patent, it sends the applicant a Notice of Allowance, which is what ENDV just received. The final steps required before the actual patent is issued are essentially a formality (applicant pays required issue fee and submits any final drawings). So essentially this news means ENDV has received patent approval.
The patent application covers the production of fully human biological molecules, including growth factors and cytokines in adult stem cells using the Company's proprietary technologies. This technology has applications from the production of biological molecules, such as cytokines for research purposes to the creation of next-generation biologics.
Daily
ENDV
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
